生物制剂治疗天疱疮与大疱性类天疱疮.pdfVIP

国隧廑丛丝痘堂塞圭2Q!垒生!旦箍箜鲞筮!塑地』Q!墅i!!!y!!!堡!!，』i坠丛!g2Q!垒：y!!：垒Q：盟!：! ·医学继续教育· 生物制剂治疗天疱疮与大疱性类天疱疮 铁·杜尔娜左亚刚 【摘要】研究显示，生物制剂治疗难治性天疱疮、类天疱疮疗效显著，其中利妥昔是一种源自基因工 程的人鼠嵌合型抗B淋巴细胞CD20的单克隆抗体，最早应用于天疱疮和类天疱疮的治疗。除利妥昔外， p38丝裂原活化蛋白激酶抑制剂KC706、PI一0824疫苗、肿瘤坏死因子拮抗剂或单克隆抗体如英夫利西等 均取得满意疗效。但应用生物制剂治疗天疱疮和类天疱疮存在严重不良反应的可能性，且价格昂贵、缺乏 一定量的可靠临床疗效的数据，影响了生物制剂在临床中的广泛应用。 【关键词】天疱疮；类天疱疮，大疱性；生物制品；治疗 of in andbullous Applicationbiologicalagentspemphigus pemphigoidT／e·Duema，ZuoYagang． of UnionMedical ofMedicalSciences DepartmentDermatology,PekingCoHegeHospital，ChineseAcademy and UnionMedical Peking College，Beijing100730,China author：Zuo Corresponding Yagang,Email：zuoyagang@263．net studieshaveshownthat are effectiveforthetreatmentof 【Abstract】Recent biologicalagentsevidently and monoclonalhuman／mousechimeric refractorypemphiguspemphigoid．Rituximab，a IgGl antibodytargeting theB—cell cell—sUrface theearliest used for andmost specific antigenCD20，is widely biologicalagent and suchas activated pemphiguspemphigoid．Besidesrituximab，otheragents infliximab，P38mitogen protein vaccineandblockersoformonoclonalantibodiestumor kinase(MAPK)inhibitorKC706，PI一0824 against necrosisfactoralsohaveexhibitedfavorable seriousadverse effects．However，potentiallyreactions，high andlackofreliableclinicaldatahavelimitedthewide of inthetreatment expense applicationbiologicalagents of and pemphiguspemphigoid． 【Keywords】Pemphigus；Pemphigoid，bullous；Biologicalproducts；Therapy